Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 14/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 14/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 14/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684347 | 1.00 | ADRA1D (0.56) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL7681613 | 0.88 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL7682614 | 0.88 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL7684365 | 0.82 | ADRA1D (0.36) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL7684360 | 0.82 | ADRA1D (0.36) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| Fumaric Acid SCHEMBL7682140 | 0.81 | ADRA1D (0.62) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| Fumaric Acid SCHEMBL7682138 | 0.81 | ADRA1D (0.62) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL6763070 | 0.78 | ADRA1D (0.76) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL6761937 | 0.78 | ADRA1D (0.76) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL6760339 | 0.76 | ADRA1D (0.59) | ADRA1DADRA1AADRA1BDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | claimed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | claimed |
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-0966470-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998040386-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | ADRA1D 105/4885ADRA1A 162/4885ADRA1B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.